Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular Identifiers

Next generation sequencing (NGS) platforms have the ability to generate almost limitless numbers of sequence reads starting with a PCR product. This gives the illusion that it is possible to analyze minor variants in a viral population. However, including a PCR step obscures the sampling depth of th...

Full description

Bibliographic Details
Main Authors: Shuntai Zhou, Ronald Swanstrom
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Viruses
Subjects:
Online Access:https://www.mdpi.com/1999-4915/12/8/850
_version_ 1797560411081408512
author Shuntai Zhou
Ronald Swanstrom
author_facet Shuntai Zhou
Ronald Swanstrom
author_sort Shuntai Zhou
collection DOAJ
description Next generation sequencing (NGS) platforms have the ability to generate almost limitless numbers of sequence reads starting with a PCR product. This gives the illusion that it is possible to analyze minor variants in a viral population. However, including a PCR step obscures the sampling depth of the viral population, the key parameter needed to understand the utility of the data set for finding minor variants. Also, these high throughput sequencing platforms are error prone at the level where minor variants are of interest, confounding the interpretation of detected minor variants. A simple strategy has been applied in multiple applications of NGS to solve these problems. Prior to PCR, individual molecules are “tagged” with a unique molecular identifier (UMI) that can be used to establish the actual sample size of viral genomes sequenced after PCR and sequencing. In addition, since PCR generates many copies of each sequence tagged to a specific UMI, a template consensus sequence (TCS) can be created from the many reads of each template, removing virtually all of the method error. From this perspective we examine our own use of a UMI, called Primer ID, in the detection of minor drug resistant variants in HIV-1 populations.
first_indexed 2024-03-10T17:59:22Z
format Article
id doaj.art-8a0500fb622f4640aab87b89998f1de6
institution Directory Open Access Journal
issn 1999-4915
language English
last_indexed 2024-03-10T17:59:22Z
publishDate 2020-08-01
publisher MDPI AG
record_format Article
series Viruses
spelling doaj.art-8a0500fb622f4640aab87b89998f1de62023-11-20T09:00:09ZengMDPI AGViruses1999-49152020-08-0112885010.3390/v12080850Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular IdentifiersShuntai Zhou0Ronald Swanstrom1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USALineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USANext generation sequencing (NGS) platforms have the ability to generate almost limitless numbers of sequence reads starting with a PCR product. This gives the illusion that it is possible to analyze minor variants in a viral population. However, including a PCR step obscures the sampling depth of the viral population, the key parameter needed to understand the utility of the data set for finding minor variants. Also, these high throughput sequencing platforms are error prone at the level where minor variants are of interest, confounding the interpretation of detected minor variants. A simple strategy has been applied in multiple applications of NGS to solve these problems. Prior to PCR, individual molecules are “tagged” with a unique molecular identifier (UMI) that can be used to establish the actual sample size of viral genomes sequenced after PCR and sequencing. In addition, since PCR generates many copies of each sequence tagged to a specific UMI, a template consensus sequence (TCS) can be created from the many reads of each template, removing virtually all of the method error. From this perspective we examine our own use of a UMI, called Primer ID, in the detection of minor drug resistant variants in HIV-1 populations.https://www.mdpi.com/1999-4915/12/8/850drug resistance mutationsunique molecular identifierprimer IDnext generation sequencingHIV
spellingShingle Shuntai Zhou
Ronald Swanstrom
Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular Identifiers
Viruses
drug resistance mutations
unique molecular identifier
primer ID
next generation sequencing
HIV
title Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular Identifiers
title_full Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular Identifiers
title_fullStr Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular Identifiers
title_full_unstemmed Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular Identifiers
title_short Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular Identifiers
title_sort fact and fiction about 1 next generation sequencing and the detection of minor drug resistant variants in hiv 1 populations with and without unique molecular identifiers
topic drug resistance mutations
unique molecular identifier
primer ID
next generation sequencing
HIV
url https://www.mdpi.com/1999-4915/12/8/850
work_keys_str_mv AT shuntaizhou factandfictionabout1nextgenerationsequencingandthedetectionofminordrugresistantvariantsinhiv1populationswithandwithoutuniquemolecularidentifiers
AT ronaldswanstrom factandfictionabout1nextgenerationsequencingandthedetectionofminordrugresistantvariantsinhiv1populationswithandwithoutuniquemolecularidentifiers